Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There has been recent growth in the number and magnitude of clinical trials for various forms of retinal gene therapy. Because of regulatory requirements, and to better understand vector safety profiles, there is a need for standardised and effective methods to collect, process, and store biological samples taken from trial patients that can be used to assess the dissemination of the vector within bodily fluids and any systemic cellular and humoral immune responses.

Original publication

DOI

10.1007/978-1-4939-7522-8_27

Type

Journal article

Journal

Methods Mol Biol

Publication Date

2018

Volume

1715

Pages

359 - 371

Keywords

AAV, Clinical trials, Gene therapy, Immunogenicity, Viral vector shedding, Dependovirus, Genetic Therapy, Genetic Vectors, Humans, Immunity, Humoral, Retina, Virus Shedding